BELLUS Health (TSE:BLU) Stock Price Crosses Below Fifty Day Moving Average of $10.41

BELLUS Health Inc. (TSE:BLUGet Rating) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$10.41 and traded as low as C$10.28. BELLUS Health shares last traded at C$10.55, with a volume of 33,500 shares.

Separately, HC Wainwright restated a “buy” rating and issued a C$16.00 price objective on shares of BELLUS Health in a report on Thursday, May 12th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of C$15.75.

The company has a debt-to-equity ratio of 0.30, a current ratio of 15.33 and a quick ratio of 14.75. The company has a market capitalization of C$1.13 billion and a PE ratio of -10.08. The stock’s 50 day simple moving average is C$10.41 and its 200-day simple moving average is C$9.27.

BELLUS Health (TSE:BLUGet Rating) last issued its quarterly earnings results on Wednesday, May 11th. The company reported C($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of C($0.23) by C$0.07. The business had revenue of C$0.01 million for the quarter, compared to analysts’ expectations of C$0.01 million. On average, equities analysts predict that BELLUS Health Inc. will post -0.95 earnings per share for the current year.

BELLUS Health Company Profile (TSE:BLU)

BELLUS Health Inc, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.

Recommended Stories

Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.